Results 71 to 80 of about 24,853 (244)

Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2

Advances in Therapy
Some Janus kinase (JAK) inhibitors such as ruxolitinib and fedratinib do not address and may worsen anemia in patients with myelofibrosis. In these cases, the JAK inhibitor may be continued at a reduced dose in an effort to maintain splenic and symptom ...
C. Harrison, A. Vannucchi, Christian Récher, Francesco Passamonti, A. Gerds, J. Hernández-Boluda, Abdulraheem M. Yacoub, S. Sirhan, Catherine E Ellis, Bharat Patel, B. Strouse, U. Platzbecker   +11 more
semanticscholar   +1 more source

LC‐OCT Features in Vitiligo: A Preliminary Report

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Vitiligo is a chronic depigmenting disorder characterized by the selective loss of melanocytes, leading to the progressive development of hypopigmented macules and patches. Line‐field confocal optical coherence tomography (LC‐OCT) is a novel imaging technique that combines the advantages of optical coherence tomography (OCT) and ...
Gerardo Palmisano, Daniele Omar Traini, Lorenzo Maria Pinto, Alessandra D'Amore, Mariano Suppa, Alessandro Di Stefani, Ketty Peris   +6 more
wiley   +1 more source

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

American Journal of Clinical Dermatology
Atopic dermatitis (AD), a highly pruritic, inflammatory skin disease, affects approximately 7% of adolescents globally. A topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, demonstrated safety and efficacy among adolescents/adults
L. Eichenfield, E. Simpson, K. Papp, Jacek C Szepietowski, A. Blauvelt, L. Kircik, J. Silverberg, E. Siegfried, M. Kuligowski, M. Venturanza, H. Kallender, Haobo Ren, A. Paller   +12 more
semanticscholar   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Senotherapeutics for Knee Osteoarthritis

Medicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman, Girish Pattappa, Patrick Pann, Stephan Reppenhagen, Maximilian Rudert, Peter Angele, Denitsa Docheva   +6 more
wiley   +1 more source

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica, 2015
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies.
Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek   +14 more
doaj   +1 more source

Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity

Biochemistry and Biophysics Reports, 2020
Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases. Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19.
Markus Fischer, Meike Luck, Maximilian Werle, Holger A. Scheidt, Peter Müller   +4 more
doaj   +1 more source

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).

Blood
In REACH4 (NCT03491215), a phase 1/2, open-label, single-arm, multicenter study, the pharmacokinetics (PK), efficacy, and safety of ruxolitinib were evaluated in treatment-naïve and steroid-refractory pediatric patients with grade II-IV acute graft ...
F. Locatelli, H. Kang, B. Bruno, Virginie Gandemer, F. Rialland-Battisti, M. Faraci, Yoshiyuki Takahashi, K. Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St Pierre, A. Prahallad, C. Díaz-de-Heredia   +14 more
semanticscholar   +1 more source

Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma

VIEW, EarlyView.
Cutaneous melanoma exhibits substantial molecular heterogeneity, and metabolic reprogramming may contribute to differences in tumor behavior and treatment response. In this study, we integrated multi‐omics data from SKCM cohorts to identify two metabolism‐associated subtypes with distinct oxidative stress profiles, immune microenvironments, prognostic ...
Qikun Gao, Ziyi Liu, Ying Xu
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source